Document is current
Any future updates will be listed below
-
Authors
Tan, Manuela M. X. https://orcid.org/0000-0001-5835-669X
Lawton, Michael A. https://orcid.org/0000-0002-3419-0354
Pollard, Miriam I.
Brown, Emmeline
Real, Raquel https://orcid.org/0000-0001-8117-742X
Carrasco, Alejandro Martinez https://orcid.org/0000-0001-6191-1703
Bekadar, Samir
Jabbari, Edwin https://orcid.org/0000-0001-6844-882X
Reynolds, Regina H. https://orcid.org/0000-0001-6470-7919
Iwaki, Hirotaka https://orcid.org/0000-0002-8982-7885
Blauwendraat, Cornelis https://orcid.org/0000-0001-9358-8111
Kanavou, Sofia
Hubbard, Leon
Malek, Naveed
Grosset, Katherine A.
Bajaj, Nin
Barker, Roger A. https://orcid.org/0000-0001-8843-7730
Burn, David J.
Bresner, Catherine https://orcid.org/0000-0003-2673-9762
Foltynie, Thomas https://orcid.org/0000-0003-0752-1813
Wood, Nicholas W. https://orcid.org/0000-0002-9500-3348
Williams-Gray, Caroline H. https://orcid.org/0000-0002-2648-9743
Andreassen, Ole A. https://orcid.org/0000-0002-4461-3568
Toft, Mathias
Elbaz, Alexis https://orcid.org/0000-0001-9724-5490
Artaud, Fanny
Brice, Alexis
Corvol, Jean-Christophe https://orcid.org/0000-0001-7325-0199
Aasly, Jan
Farrer, Matthew J. https://orcid.org/0000-0003-1159-5321
Nalls, Michael A. https://orcid.org/0000-0003-0319-4325
Singleton, Andrew B.
Williams, Nigel M. https://orcid.org/0000-0003-1177-6931
Ben-Shlomo, Yoav
Hardy, John https://orcid.org/0000-0002-3122-0423
Hu, Michele T. M.
Grosset, Donald G.
Shoai, Maryam https://orcid.org/0000-0003-2499-8533
Pihlstrøm, Lasse https://orcid.org/0000-0002-7635-8645
Morris, Huw R. https://orcid.org/0000-0002-5473-3774
-
Funding
Funding for this research was provided by:
Parkinson’s UK (H-1703)
Ministry of Health and Care Services | Helse Sør-Øst RHF
NIHR Cambridge Biomedical Research Centre
RCUK | Medical Research Council (MR/R007446/1)
Data Tecnica International LLC
Parkinson’s UK
Cure Parkinson’s Trust
- License Information
-
More Information
Article History
Received: 5 February 2024
Accepted: 24 May 2024
First Online: 7 June 2024
Competing interests
: MMXT is employed by Oslo University Hospital. She has received grant support from Parkinson’s UK, the Michael J Fox Foundation, and South-Eastern Norway Regional Health Authority (Helse Sør-Øst). MAL received fees for advising on a secondary analysis of an RCT sponsored by North Bristol NHS trust. KG is an independent medical consultant and receives payments from the University of Glasgow. She has no other fees or honoraria to report. J-CC has served on advisory boards for Biogen, Denali, Idorsia, Prevail Therapeutic, Servier, Theranexus, UCB; and received grants from Sanofi and the Michael J Fox Foundation outside of this work. RHR is currently employed by CoSyne Therapeutics (Lead Computational Biologist). All work performed for this publication was performed in her own time, and not as a part of her duties as an employee. MAN’s participation in this project was part of a competitive contract awarded to DataTecnica LLC by the National Institutes of Health to support open science research. MAN also currently serves on the scientific advisory board for Character Bio Inc and is a scientific founder at Neuron23 Inc and owns stock. ABS is Associate Editor of npj Parkinson’s Disease. ABS was not involved in the journal’s review of, or decisions related to, this manuscript. OAA is a consultant to HealthLytix. CWG is employed by the University of Cambridge and supported by the Medical Research Council (MR/R007446/1 and MR/W029235/1) and the NIHR Cambridge Biomedical Research Centre (NIHR 203312). She has received research funding from the Cambridge Centre for Parkinson-Plus, Cure Parkinson’s, Parkinson’s UK, The Evelyn Trust, The Rosetrees Trust, Addenbrooke’s Charitable Trust and the Michael J Fox Foundation; speaker payments from GSK and World Parkinson’s Coalition; and consulting fees from Evidera Inc. RAB has served as an advisor to UCB; BlueRock Therapeutics; Novo Nordisk; Aspen Neuroscience, UCB and Transine Therapeutics. He has received lecture fees from Novo Nordisk. He has received grant support from the MRC, Wellcome, Parkinson’s UK, Cure Parkinson’s Trust, EU, Novo Nordisk, DRI, and ASAP. This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. He has received royalties from Wiley and Springer-Nature. DGG is an employee of the University of Glasgow. In the past 12 months, he reports consultancy fees from the Glasgow Memory Clinic; honoraria for chairing or attending meetings from AbbVie and BIAL Pharma. LP has received grant support from the National Health Association, Norway, the Michael J Fox Foundation, and South-Eastern Norway Regional Health Authority (Helse Sør-Øst). HRM is employed by UCL. In the last 12 months, he reports paid consultancy from Roche and Amylyx; lecture fees/honoraria - BMJ, Kyowa Kirin, Movement Disorders Society. Research Grants from Parkinson’s UK, Cure Parkinson’s Trust, PSP Association, Medical Research Council, Michael J Fox Foundation. HRM is a co-applicant on a patent application related to C9ORF72 - Method for diagnosing a neurodegenerative disease (PCT/GB2012/052140).
